OBJECTIVE: Vaccination of young women (15–25 years of age) against human
papillomavirus (HPV) has been shown to be very efficacious in preventing the development …

The immunogenicity and safety of an HPV-16/18 AS04-adjuvanted vaccine were assessed
in women aged 26–55 years and compared with women aged 15–25 years in a Phase III …

In the recent period following the approval of the first vaccine targeted against human
papillomavirus, it is imperative that we re-evaluate the past, present, and future of cervical …

Human papillomavirus (HPV) vaccines have been shown to be both highly effective and
safe, and there is now considerable enthusiasm among healthcare providers to use the …

Background The impact of the prophylactic vaccine against human papillomavirus (HPV)
types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was …

Background Although adolescent girls are the main population for prophylactic human
papillomavirus (HPV) vaccines, adult women who remain at risk of cervical cancer can also …

1008 Background: Genital HPV infections can be acquired shortly after sexual debut, and
the risk remains throughout a sexually active woman's lifetime. In women 15–25 years of …

HPV vaccination of pre-pubescent girls will be effective for many girls. Vaccinating girls and
women older than 12 years of age may accelerate the reduction in cervical cancer rates …

We report efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3
years post-vaccination. The study was conducted in a population (N= 433) of women …

OBJECTIVES: To review concepts, information, obstacles, and approaches to cervical
cancer screening and prevention as vaccination against human papillomavirus (HPV) types …